αglucosidase

Acarbose (BAY g 5421) is an inhibitor of α-Glucosidases with antihyperglycemic activity.

Hexylresorcinol (4-Hexylresorcinol) is a substituted dihydroxybenzene utilized topically as an antiseptic for minor skin infection treatment.

1-Deoxynojirimycin (Moranoline) is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.

1. 3-Butylidenephthalide (Butylidene phthalide) has antihyperglycemic effect is due to inhibition of α-glucosidase at the intestinal level, inhibited the activity of yeast-α-glucosidase (IC(5) 2.35 mM) in a noncompetitive fashion with a K(i) of 4.86 mM.

Voglibose (Glustat), an N-substituted derivative of valiolamine, exhibits excellent inhibitory activity against α-glucosidases and action against hyperglycemia and various disorders caused by hyperglycemia.

α-Glucosidase (α-D-Glucosidase) is a carbohydrate hydrolyzing enzyme that catalyzes the release of α-glucose from the non-reducing end of the substrate, playing a vital role in glucose absorption by the small intestine. Inhibiting α-Glucosidase effectively manages non-insulin-dependent diabetes mellitus (NIDDM).

Licochalcone C (LICOCHALCONEC) has potent antioxidant properties and inhibition of bacterial growth and cellular respiration. It has cardioprotection effect, via antioxidant, anti-inflammatory, and anti-apoptotic activities. Licochalcone C exhibit inhibitory activity with cytotoxicity in a rat basophilic leukaemia cell line, RBL-2H3. Licochalcone C induces apoptosis via B-cell lymphoma 2 family proteins in T24 cells, it may be a potential adjuvant therapeutic agent for bladder cancer.

β-Glucosidase is a glucoside bond hydrolase widely found in organisms and is involved in glucose metabolism, which can be used to study diseases caused by abnormal glucose metabolism.

Glucocerebrosidase-IN-1 (compound 11a) hydrochloride is a potent and selective glucocerebrosidase (GCase) inhibitor with IC50 of 29.3 μM and Ki of 18.5 μM, used in the research of Gaucher disease (GD) and Parkinson's disease (PD) [1].

α-Glucosidase-IN-26 (Compound 7i), with an IC50 value of 4.63 µM, functions as an α-glucosidase inhibitor and is utilized in type 2 diabetes mellitus (T2DM) research [1].

α-Glucosidase-IN-28 (Compound 18) is an α-glucosidase inhibitor with an IC50 of 0.62 μM and Ki of 3.93 μM, interacting with the enzyme's original binding site (OBS) and forming multiple hydrophobic interactions with adjacent amino acids. This compound is used in diabetes and related diseases research [1].

α-Glucosidase-IN-29 (compound 19) is an inhibitor of α-glucosidases with an IC50 of 1.21 μM and a Ki of 1.80 μM, used in diabetes and related disease research [1].

α-Glucosidase-IN-31 (compound R1) is a potent oral α-Glucosidase inhibitor with an IC50 of 10.1 μM, demonstrating significant blood glucose reduction and antidiabetic activity [1].

α-Glucosidase-IN-33 (compound 7c), with an IC50 of 2.39 μM, is a potent α-glucosidase inhibitor, pertinent to type 2 diabetes and hyperglycemia research [1].

α-Glucosidase-IN-34 (compound 7f) is a potent α-glucosidase inhibitor with an IC50 of 2.90 μM, applicable in type 2 diabetes and hyperglycemia research [1].

α-Amylase α-Glucosidase-IN-5 (compound 4l) functions as a dual inhibitor, effectively inhibiting both α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50 values of 5.96 μM and 1.62 μM, respectively, exhibiting potential for antidiabetic activity [1].

α-Glucosidase-IN-36 (compound 5g) is a potent inhibitor of α-glucosidase, with an IC50 value of 6.69 ± 0.18 μM and inhibition constants (Ki and Kis) of 1.65 μM and 4.54 μM, respectively. It likely suppresses α-glucosidase by interacting with its active site and altering the enzyme's secondary structure. The compound is relevant for research on type 2 diabetes mellitus (T2DM) [1].

α-Amylase α-Glucosidase-IN-3 (Compound 17) is a dual inhibitor of α-Amylase and α-Glucosidase, with IC50 values of 0.70 μM and 1.10 μM, respectively, applicable for type-II diabetes mellitus research [1].

α-Glucosidase-IN-27 (compound 8l), an α-glucosidase inhibitor with an IC50 of 25.78 μM, demonstrates potential for type 2 diabetes (D2M) research [1].

α-Glucosidase-IN-25 (Compound (R)-8k) acts as a competitive inhibitor for α-glucosidase with an inhibitory concentration 50 (IC50) of 1.19 μM, making it applicable in anti-diabetic research [1].

α-Glucosidase-IN-30 (compound 8c) is a potent, orally active competitive inhibitor of α-glucosidase, with a K i of 40.0 µM and an IC50 of 49.0 µM. Non-cytotoxic to both cancerous MCF-7 and normal HDF cell lines, it is suitable for Type 2 diabetes research [1].

α-Amylase α-Glucosidase-IN-4 (compound 5), a dual inhibitor targeting α-amylase (Amylases) and α-glucosidase (Glucosidase), exhibits potent inhibition with IC50 values of 1.10 μM and 0.15 μM respectively, and is noted for its potential antidiabetic activity [1].

Compound 56 (Antidiabetic agent 2) is a glucose-uptake promoter that inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase, with IC50 values of 0.036, 0.042, 0.241, and 0.185 μM, respectively. This agent effectively decreases blood glucose levels [1].

α-Glucosidase-IN-32 (compound f26) is a reversible, noncompetitive inhibitor of α-glucosidase that is orally active with an IC50 of 3.07 μM. It forms a complex with α-glucosidase via hydrogen bonding and hydrophobic interactions, inducing conformational and secondary structure changes that inhibit the enzyme's activity. This compound is utilized in diabetic disease research [1].